Skip to main content
Premium Trial:

Request an Annual Quote

RNAi Delivery Firm Traversa Raises $2M

NEW YORK (GenomeWeb News) – Traversa Therapeutics, a La Jolla, Calif.-based developer of RNAi delivery technologies, today announced that it has raised $2 million in a Series A financing round.
 
Traversa’s technology was developed by Steven Dowdy, a Howard Hughes Medical Institute investigator at the University of California, San Diego.
 
“The technology has received an outstanding level of interest for use with human therapeutics, and as a high-throughput screening reagent, providing the company with both long-term growth prospects and a short-term revenue stream to augment this financing,” Hans Petersen, president and CEO of Traversa, said in a statement.
 
The financing was led by San Diego Tech Coast Angels, with additional funding coming from Mesa Verde Venture Partners and Morningside Group.
 
The firm also said that Francois Ferre, co-CEO of Althea and lead angel investor, has joined its board.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.